Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
With a $650 million cost savings program launching in 2026, six regulatory decisions expected this year,and two Phase 3 assets with blockbuster potential, the stock trades at a 17% discount to peer-average EV EBITDA. Closing that gap alone implies a stock price above $20 46% upside from current levels. The market still prices Viatris as a declining generics house burdened by merger-era debt. The reality is acompany generating $2.2 billion in annual free cash flow, aggressively buying back shares, building a differentiated specialty pipeline through its unmatched global distribution infrastructure, and approaching a genuine inflection point in 2026. The Defining KPI: 13.5% Free Cash Flow Yield Warning! GuruFocus has detected 4 Warning Signs with VTRS. Is VTRS fairly valued? Test your thesis with our free DCF calculator. If one number captures the bull case, it is the free cash flow yield of 13.5%. Viatris generated $2.2 billionin free cash flow (excluding transaction costs)
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026 [Yahoo! Finance]Yahoo! Finance
- Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- Viatris Stock: Is VTRS Outperforming the Health Care Sector? [Yahoo! Finance]Yahoo! Finance
- Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 2/26/26 - Beat
VTRS
Sec Filings
- 4/2/26 - Form ARS
- 4/2/26 - Form DEFA14A
- 4/2/26 - Form DEF
- VTRS's page on the SEC website